1. Vestbo J,Hurd SS, Agustf AG et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347–65.
2. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–52.
3. Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004; 23: 698–702.
4. Wouters EF. The burden of COPD in The Netherlands: results from the confronting COPD survey. Respir Med 2003; 97 (Suppl. C): S51–59.
5. Blackwell TS, Blackwell TR, Holden EP et al. In vivo antioxidant treatment suppresses nuclear factor-kappa B activation and neutrophilic lung inflammation. J Immunol 1996; 157: 1630–377.
6. van Overveld FJ, Demkow U, Gorecka D et al. New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine. J Physiol Pharmacol 2005; 56 (Suppl. 4): 135–42.
7. Dekhuijzen PNR. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J 2004; 23: 629–36.
8. Ueno T, Yamada M, Igarashi Y, Ogawa T. N-acetylcysteine protects osteoblastic function from oxidative stress. J Biomed Mater Res A 2011; 99: 523–31.
9. Sadowska AM, Manuel-Y-Keenoy B, De Backer WA. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review. Pulm Pharmacol Ther 2007; 20: 9–22.
10. Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 2000; 22: 209–21.
11. Gerrits CM, Herings RM, Leufkens HG, Lammers JW. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 795–98.
12. Decramer M, Rutten-van Mölken M, Dekhuijzen PN et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomised on N-acetylcysteine Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365: 1552–60.
13. Schermer T, Chavannes N, Dekhuijzen R et al. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. Respir Med 2009; 103: 542–51.
14. Zuin R, Palamidese A, Negrin R et al. High dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease. Clin DrugInvestig 2005; 25: 401–8.
15. Zheng JP, Wen FQ, Bai CX et al. High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON study. COPD 2013; 10: 164–71.
16. Anthonisen NR, Manfreda J, Warren CPW et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196–204.
17. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J 2003; 21 (Suppl. 41): 46–53.
18. Zheng JP, Kang J, Huang SG et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet 2008; 371: 2013–18.
19. Calverley PM, Anderson JA, Celli B et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–89.
20. Tashkin DP, Celli B, Senn S et al, for the UPLIFT study investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543–54.
21. Zhou Y, Wang X, Zeng X et al. Positive benefits of theophylline in a randomised, double-blind, parallel-group, placebo controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology 2006; 11: 603–10.
22. Tse HN, Raiteri L, Wong KY et al. High-dose N-acetylcysteine in stable chronic obstructive pulmonary disease: the 1-year, double-blind, randomised, placebo-controlled HIACE study. Chest 2013; 144: 106–18.
23. Jenkins CR, Jones PW, Calverley PM et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009; 10: 59.
24. Decramer M, Celli B, Kesten S et al, for the UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171–78.
25. Zheng JP, Zhong NS, Jiang M, Zeng GQ. Carbocisteine for acute exacerbations of COPD – authors' reply. Lancet 2008; 372: 1631–32.
26. Hurst JR, Vestbo J, Anzueto A et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128–38.
27. Zheng JP, Yang L, Wu YM et al. The efficacy and safety of combination salmeterol (50 μg)/fluticasone propionate (500 μg) inhalation twice daily via Accuhaler in Chinese patients with COPD. Chest 2007; 132: 1756–63.
28. Zhong N, Wang C, Yao W et al. Prevalence of chronic obstructive pulmonary disease in China: a large population-based survey. Am J Respir Crit Care Med 2007; 176: 753–60.
29. Calverley P, Pauwels R, Vestbo J et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449–56.
30. Thomsen M, Nordestgaard BG, Vestbo J et al. Characteristics and outcomes of chronic obstructive pulmonary disease in never smokers in Denmark: a prospective population study. Lancet Respir Med 2013; 1: 543–50.
31. Zhong N, Zheng J, Wen F et al. Efficacy and safety of budesonide/ formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Curr Med Res Opin 2012; 28: 257–65.
32. Stav D, Raz M. Effect of N-acetylcysteine on air trapping in COPD: a randomised placebo-controlled study. Chest 2009; 136: 381–86.
33. Mata M, Sarrion I, Armengot M et al. Respiratory syncytial virus inhibits ciliagenesis in differentiated normal human bronchial epithelial cells: effectiveness of N-acetylcysteine. PLoS One 2012; 7: e48037.

Jin-Ping Zheng1, Fu-Qiang Wen2, Chun-Xue Bai3, Huan-Ying Wan4, Jian Kang5, Ping Chen6, Wan-Zhen Yao7, Li-jun Ma8, Xia Li9, Luca Raiteri10, Marco Sardina10, Yi Gao1, Bai-Song Wang11, Nan-Shan Zhong1 от имени и по поручению исследовательской группы PANTHEON
1. State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;
2. West China Hospital, Sichuan University, Chengdu, China;
3. Zhongshan Hospital, Fudan University, Shanghai, China;
4. Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China;
5. First Affiliated Hospital of China Medical University, Shenyang, China;
6. Shenyang PLA General Hospital, Shenyang, China
7. Peking University Third Hospital, Beijing, China;
8. Henan Provincial People's Hospital, Zhengzhou, China;
9. Hainan Zambon Pharmaceutical, Beijing, China;
10. Innovation & Medical Sciences Department, Zambon, Bresso, Milan, Italy;
11. MedKey Med-Tec Development, Shanghai, China